Newsroom
Follow us as we passionately pursue our goal of improving life for those with cancer.
Get the latest
-
AVEO Pharmaceuticals to Present at the 8th Annual Needham & Company Life Sciences Conference
Download PDF CAMBRIDGE, Mass., June 5, 2009 – AVEO Pharmaceuticals, Inc. today announced that Elan Ezickson, chief business officer, is scheduled to present at the 8th Annual Needham & Company Life Sciences Conference on Thursday, June 11, 2009 at 9:00 a.m. (EDT) at the New York Palace Hotel in New York City. About AVEO AVEO…
-
AV-951 Demonstrates Prolonged Progression-Free Survival and Excellent Safety Profile in Patients with Advanced Kidney Cancer; Phase 2 Data Presented at ASCO
Download PDF Results Show Median Progression-Free Survival of 11.8 Months; Tivozanib Designated as Generic Name for AV-951 CAMBRIDGE, Mass., May 29, 2009> – AVEO Pharmaceuticals, Inc., a biopharmaceutical company leveraging breakthrough discoveries in cancer biology to discover, develop and commercialize targeted oncology therapies, today announced additional data from its Phase 2 clinical trial of tivozanib…
-
AVEO Pharmaceuticals to Present at Several Key Upcoming Medical and Industry Conferences
Download PDF Progression-free Survival Data from AV-951 Phase 2 Trial in Advanced Kidney Cancer to be Highlighted at ASCO CAMBRIDGE, Mass., May 18, 2009– AVEO Pharmaceuticals, Inc., a biopharmaceutical company leveraging breakthrough discoveries in cancer biology to discover, develop and commercialize targeted oncology therapies, today announced that the company will be participating in several upcoming…
-
AVEO Pharmaceuticals’ Scientific Advisory Board Members Recognized for Contributions to Cancer Research and Medicine
Download PDF SAB Members Elected to NAS and IOM; Honored with Awards from AACR and NFCR CAMBRIDGE, Mass., May 13, 2009 – AVEO Pharmaceuticals, Inc., a biopharmaceutical company leveraging breakthrough discoveries in cancer biology to discover, develop and commercialize targeted oncology therapies, today announced that members of its Scientific Advisory Board (SAB) have been newly…
-
AVEO Announces Positive Finding for Triple VEGF Receptor Inhibitor AV-951
Download PDF Data Presented at AACR Annual Meeting; Suggests Additional Therapeutic Potentialfor AV-951 DENVER, Col., April 21, 2009 – AVEO Pharmaceuticals, Inc., a biopharmaceutical company leveraging breakthrough discoveries in cancer biology to discover, develop and commercialize targeted oncology therapies, today announced data from its proprietary preclinical models which demonstrates that the company’s potent and selective…
-
AVEO Presents Novel HGF Model and Promising Preclinical Activity to Support Lead Antibody Agent SCH 900105 (AV-299)
Download PDF FGFR-2 Target Identification and Response Data Also Highlighted; Data Presented at AACR Annual Meeting DENVER, Col, April 19, 2009 – AVEO Pharmaceuticals, Inc., a biopharmaceutical company leveraging breakthrough discoveries in cancer biology to discover, develop and commercialize targeted oncology therapies, today presented a novel human hepatocyte growth factor (HGF) knock-in model and announced…
-
Data on AVEO Pharmaceuticals’ AV-951 in Liver Cancer Model and Preclinical Activity in SCH 900105 (AV-299) to be Presented at AACR 100th Annual Meeting
Download PDF CAMBRIDGE, Mass., April 9, 2009 – AVEO Pharmaceuticals, Inc., a biopharmaceutical company leveraging breakthrough discoveries in cancer biology to discover, develop and commercialize targeted oncology therapies, today announced that it will present during two educational sessions, nine poster sessions and a minisymposium at the American Association for Cancer Research (AACR) 100th Annual Meeting…
-
Breakthrough Preclinical Model for Human Cancer May Dramatically Improve Development of Effective Oncology Drugs; Data Published in PNAS
Download PDF AVEO Scientists Generate Human Tumors in Mice from Primary Human Breast Tissue; Provides More Realistic Genetic Context in which to Evaluate New Anti-tumor Therapies CAMBRIDGE, Mass., April 6, 2009 – AVEO Pharmaceuticals, Inc., a biopharmaceutical company leveraging breakthrough discoveries in cancer biology to discover, develop and commercialize targeted oncology therapies, today announced findings…
Follow us on social media
Media inquiries
For media inquiries, please contact:
John F. Kouten, CEO
JFK Communications, Inc.
jfkouten@jfkhealth.com
Direct: 609-241-7352
Download our media kit:
Meet our leadership team
The AVEO oncology management team comprises executives with years of oncology and pharmaceutical industry experience and expertise with a proven track record for success in bringing important new therapies to patients.